Human Molecular Genetics Advance Access originally published online on February 27, 2006
Human Molecular Genetics 2006 15(7):1217-1224; doi:10.1093/hmg/ddl037
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibility
1Department of Genetics, Microbiology and Toxicology, Arrhenius Laboratory, Stockholm University, S-106 91 Stockholm, Sweden and 2The Institute for Cancer Studies, University of Sheffield, Medical School, Beech Hill Road, Sheffield S10 2RX, UK
* To whom correspondence should be addressed at: Department of Genetics, Microbiology and Toxicology, Arrhenius Laboratory, Svante Arrheniusv. 16-18, S-106 91 Stockholm, Sweden. Tel: +46 8162914; Fax: +46 8164315; Email: helleday{at}gmt.su.se
Received January 12, 2006; Accepted February 16, 2006
The XRCC3 variant T241M, but not D213N, has been reported to be associated with an increased risk of some cancers. XRCC3 is one out of five RAD51 paralogues and is involved in homologous recombination, as are the BRCA1 and BRCA2 proteins. However, in contrast to mutations in BRCA1 and BRCA2, the XRCC3T241M protein is proficient in homologous recombination and reverts sensitivity to mitomycin C found in XRCC3-deficient cells, whereas XRCC3D213N is defective in homologous recombination. Here, we report that both the XRCC3 D213N and T241M alleles are associated with an increase in centrosome number and binucleated cells. However, only the D213N allele gives an increase in spontaneous levels of apoptosis. We suggest that the inability of XRCC3 T241M to apoptotically eliminate aberrant cells with mitotic defects could increase cancer susceptibility in individuals carrying this variant. In contrast, cells carrying the XRCC3 D213N variant are able to eliminate aberrant cells by apoptosis, and consistent with this observation, this variant does not seem to be associated with cancer susceptibility.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
H. Huang, L. Fletcher, N. Beeharry, R. Daniel, G. Kao, T. J. Yen, and R. J. Muschel Abnormal Cytokinesis after X-Irradiation in Tumor Cells that Override the G2 DNA Damage Checkpoint Cancer Res., May 15, 2008; 68(10): 3724 - 3732. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Mateuca, M. Roelants, G. Iarmarcovai, P. V. Aka, L. Godderis, A. Tremp, S. Bonassi, M. Fenech, J.-L. Berge-Lefranc, and M. Kirsch-Volders hOGG1326, XRCC1399 and XRCC3241 polymorphisms influence micronucleus frequencies in human lymphocytes in vivo Mutagenesis, January 1, 2008; 23(1): 35 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wiese, J. M. Hinz, R. S. Tebbs, P. B. Nham, S. S. Urbin, D. W. Collins, L. H. Thompson, and D. Schild Disparate requirements for the Walker A and B ATPase motifs of human RAD51D in homologous recombination. Nucleic Acids Res., January 1, 2006; 34(9): 2833 - 2843. [Abstract] [Full Text] [PDF] |
||||


